{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T17:04:12Z","timestamp":1648832652810},"reference-count":5,"publisher":"American Medical Association (AMA)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Intern Med"],"published-print":{"date-parts":[[2018,6,1]]},"DOI":"10.1001\/jamainternmed.2018.2029","type":"journal-article","created":{"date-parts":[[2018,6,4]],"date-time":"2018-06-04T12:48:19Z","timestamp":1528116499000},"page":"873","source":"Crossref","is-referenced-by-count":0,"title":["Cost-effectiveness of the Adjuvanted Herpes Zoster Subunit Vaccine"],"prefix":"10.1001","volume":"178","author":[{"given":"Chester B.","family":"Good","sequence":"first","affiliation":[{"name":"Center for Value Based Pharmacy Initiatives, University of Pittsburgh Medical Center Health Plan, Pittsburgh, Pennsylvania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Inmaculada","family":"Hernandez","sequence":"additional","affiliation":[{"name":"Department of Pharmacy and Therapeutics, School of Pharmacy, University of Pittsburgh, Pittsburgh, Pennsylvania"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"10","reference":[{"issue":"2","key":"ile180035r1","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1001\/jamainternmed.2017.7431","article-title":"Cost-effectiveness of the adjuvanted herpes zoster subunit vaccine in older adults.","volume":"178","author":"Le","year":"2018","journal-title":"JAMA Intern Med"},{"issue":"2","key":"ile180035r2","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1001\/jamainternmed.2017.7442","article-title":"Evolution of herpes zoster vaccines and their economic value.","volume":"178","author":"Najafzadeh","year":"2018","journal-title":"JAMA Intern Med"},{"issue":"22","key":"ile180035r3","doi-asserted-by":"publisher","first-page":"2271","DOI":"10.1056\/NEJMoa051016","article-title":"A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults.","volume":"352","author":"Oxman","year":"2005","journal-title":"N Engl J Med"},{"issue":"1","key":"ile180035r4","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1056\/NEJMc076176","article-title":"Varicella-zoster vaccine.","volume":"357","author":"Woo","year":"2007","journal-title":"N Engl J Med"},{"key":"ile180035r5","unstructured":"US Food and Drug Administration Approved Prescribing Information for Zostavax [zoster vaccine live (Oka\/Merck)]. Whitehouse Station, NJ: Merck, May 2006. https:\/\/www.fda.gov\/downloads\/biologicsbloodvaccines\/vaccines\/approvedproducts\/ucm132831.pdf. Accessed February 21, 2018."}],"container-title":["JAMA Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamainternalmedicine\/fullarticle\/2682152","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,6,4]],"date-time":"2018-06-04T12:48:28Z","timestamp":1528116508000},"score":1,"resource":{"primary":{"URL":"http:\/\/archinte.jamanetwork.com\/article.aspx?doi=10.1001\/jamainternmed.2018.2029"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6,1]]},"references-count":5,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018,6,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamainternmed.2018.2029","relation":{},"ISSN":["2168-6106"],"issn-type":[{"value":"2168-6106","type":"print"}],"subject":[],"published":{"date-parts":[[2018,6,1]]}}}